RxDoctor Payments Data

Catherine Oplinger

Psychiatric/Mental Health · Muncie, INNPI 1821167073

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 408 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,154in general payments, 2019–2025

Across 408 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Supernus Pharmaceuticals, Inc.$590
  • Johnson & Johnson$554
  • Corium, LLC$550
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$528
  • Otsuka America Pharmaceutical, Inc.$505
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$6,08899%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,154 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate18$31,303
VraylarCariprazine Hcl14$19,908
VyvanseLisdexamfetamine Dimesylate14$5,340
Duloxetine Hcl29$1,212
Aripiprazole20$1,094
Lamotrigine38$929
Bupropion XlBupropion Hcl48$829
Alprazolam65$667
Clonazepam67$580
Trazodone Hcl38$400
Quetiapine Fumarate20$318
Escitalopram Oxalate27$314
Buspirone Hcl13$278
Lorazepam53$249
Gabapentin11$227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$528$31,30318 claims
AbbVieVraylar$1,308$19,90814 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$98$5,34014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →